COVID‑19 and comorbid chronic diseases


ABSTRACT. This literature review includes the latest studies and meta-analyses, dedicated to the problem of comorbidity in coronavirus disease (COVID‑19). The most often comorbid conditions that accompany severe and fatal cases of COVID‑19 include arterial hypertension (AH), diabetes mellitus (DM), ischemic heart disease (IHD), brain infarction, chronic bronchitis /сhronic obstructive lung disease. These diseases share some common features like proinflammatory condition and the deterioration of innate immunity. Mechanisms of unfavorable influence of DM, AH, IHD and chronic obstructive pulmonary disease on the course of COVID‑19 include the imbalance of biochemical cascades of angiotensin-converting enzyme 2 and so-called cytokine storm, induced by glucolipid metabolic disturbances. Revealing of causality between chronic diseases and severe course of COVID‑19 in future studies can help health system providers to find the susceptible population, to estimate the risk of deterioration of clinical condition and to prescribe the preventive measures (for instance, vaccination of high-risk individuals from influenza and, in the future, from COVID‑19). Severe course of COVID‑19 and high mortality in multimorbid patients underline the need in the strict control of their basic biological parameters (arterial pressure, fasting plasma glucose etc.). Apart from that, with the aim of minimization of infection risk these patients need to imply stricter quarantine and shielding measures than the relatively healthy people. Medical workers should also emphasize on telemedicine technologies in management of such patients.

Keywords: comorbidity, COVID‑19, chronic diseases, arterial hypertension, diabetes mellitus, ischemic heart disease.


Guan W.J., Ni Z.Y., Hu Y., et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J Med. 2020; 382: 1708-1720.

Deng S.-Q., Peng H.-J. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. Journal of Clinical Medicine. 2020; 9 (2): 575.

Peng Y.D., Meng K., Guan H.Q., et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Chinese Journal of Cardiology. 2020; 48(6): 450-455.

Odegaard J., Chawla A. Connecting type 1 and type 2 diabetes through innate immunity. Cold Spring Harbor Perspect Med. 2012; 2 (3): a007724.

Hong K.W., Cheong H.J., Choi W.S., Lee J., Wie S.H., Baek J.H. Clinical courses and outcomes of hospitalized adult patients with seasonal influenza in Korea, 2011-2012: Hospital-based Influenza Morbidity & Mortality (HIMM) surveillance. J Infect Chemothe. 2014; 20: 9–14.

Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497-506.

Wang D., Hu B., Hu C., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama. 2020; 323: 1061–1069.

Yang J., Zheng Y., Gou X., et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020; 94: 91–95.

Chen Y., Gong X., Wang L., Guo J. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis. medRxiv. 2020; 03 (25): 20043133.

Jiang F., Yang J., Zhang Y., et al. Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nature reviews Cardiology. 2014; 11: 413-426.

Imai Y., Kuba K., Rao S., et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005; 436: 112-116.

Patel V.B., Zhong J.C., Grant M.B., Oudit G.Y. Role of the ACE2/Angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circulation research. 2016; 118: 1313-1326.

Wrapp D., Wang N., Corbett K.S., et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367:1260-1263.

O'Mara G. Could ACE inhibitors and particularly ARBs increase susceptibility to COVID-19 infection? BMJ. 2020; 368: m406.

Sommerstein R. Preventing a COVID-19 pandemic. BMJ. 2020; 368: m810.

Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020; 8: e21.

De Abajo F., Rodriguez-Martin S., Lerma V., et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. The Lancet. 2020; 395: 1705-1714.

Zhang J.J., Dong X., Cao Y.Y., et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020; 75 (7): 1730-1741.

Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054–1062.

Gurwitz D. Angiotensin receptor blockers as tentative SARS-COV-2 therapeutics. Drug Dev Res. 2020; 81(5): 537-540.

Fosbøl E.L., Butt J.H., Østergaard L., et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA. 2020; 324(2): 168–177.

Li J., Wang X., Chen J., et al. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020; 5 (7): 825-830.

Mancia G., Rea F., Ludergnani M., et al. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. N. Engl. J Med. 2020; 382(25): 2431-2440.

Mehta N., Kalra A., Nowacki A., et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020: e201855.

Reynolds H., Adhikari S., Pulgarin C., et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. N. Engl. J Med. 2020; 382 (25): 2441-2448.

Hippisley-Cox J., Young D., Coupland C., et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020; 106: 1503-1511.

Vaduganathan M., Vardeny O., Michel T., et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N. Engl. J Med. 2020; 382: 1653-1659.

Bozkurt B., Kovacs R., Harrington R. HFSA/ACC/AHA statement addresses concerns Re: using RAAS antagonists in COVID-19. J Card Fail. 2020; 26(5): 370.

European Society of Cardiology. Position statement of the ESC council on hypertension on ACE-inhibitors and angiotensin receptor blockers. (2020). Available at: Coronavirus (COVID-19) ACEi/ARB investigation (CORONACION). identifier: NCT04330300. ACE inhibitors or ARBs discontinuation in context of SARS-CoV-2 pandemic (ACORES-2). identifier: NCT04329195. Losartan for patients with COVID-19 not requiring hospitalization. identifier: NCT04311177.

Guo J. Research progress on prevention and treatment of glucolipid metabolic disease with integrated traditional Chinese and Western medicine. Chin J Integr Med. 2017; 23: 403-409.

Specification of diagnosis and treatment of glucolipid metabolic disorders (Dan-Zhuo) with integrated Chinese and Western medicine. World Chinese Medicine. 2019; 14: 771-782.

Donath M.Y., Dinarello C.A., Mandrup-Poulsen T. Targeting innate immune mediators in type 1 and type 2 diabetes. Nature reviews Immunology. 2019; 19: 734-46.

Drummond G., Vinh A., Guzik T., Sobey C. Immune mechanisms of hypertension. Nature reviews Immunology. 2019; 19: 517-32.

Xu Z., Shi L., Wang Y., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory medicine. 2020; 8 (4): 420-422.

Alqahtani J., Oyelade T., Aldhahir A., et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One 2020; 15: e0233147.

Guan W.J., Liang W.H., Zhao Y., et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur. Respir. J. 2020; 55: 2000547.

Restrepo M., Mortensen E., Pugh J., Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur. Respir. J. 2006; 28: 346–351.

Restrepo M., Sibila O., Anzueto A. Pneumonia in patients with chronic obstructive pulmonary disease. Tuberc. Respir. Dis. 2018; 81: 187–197.

Wan Y., Shang J., Graham R., et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020; 94(7): e00127-20.

Toru Ü., Ayada C., Genç O. et al. Serum levels of RAAS components in COPD. Eur. Respir. J. 2015; 46: PA3970.

Lippi G, Henry B. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir. Med. 2020; 167: 105941.

Williamson E., Walker A., Bhaskaran K., et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020; 584: 430–436.

Matsumoto H., Saito K. Does asthma affect morbidity or severity of COVID-19? The Journal of Allergy and Clinical Immunology. 2020; 146(1): 55-57.

Beurnier A., Jutant M., Jevnikar M., et al. Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalization. European Respiratory Journal. 2020. In press.

How to Cite
Zaikov, S. V. (2020). COVID‑19 and comorbid chronic diseases. Infusion & Chemotherapy, (3), 5-10.

Author Biography

S. V. Zaikov, National Medical Academy of Postgraduate Education named after P. L. Shupyk, Kyiv, Ukraine

Zaikov Sergii Viktorovych
Professor of the Department of Phthisiology and Pulmonology
Doctor of medicine
10, M. Amosova st., Kyiv, 03038, Ukraine.